TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: % of Syllables Stuttered (%SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of subcutaneous vedolizumab treatment in clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in motor-evoked potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in functional mapping of phantom limb cortical areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Number of Participant Reported CMRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Communication Confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Worries
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of active Retinopathy of Prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Absence of unfavorable structural outcomes in both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Kamperos's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frailty Phenotype (FP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Study of Osteoporotic Fractures (SOF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Kihon Checklist (KCL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Continued Access to Atezolizumab-based Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tumor Shrinkage Rate (TSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects achieving ACR 20 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood chemistry tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute and late gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute and late urinary toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pulse Rate Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and individual usability score of ≥3 in the usability questionnaire in ≥80% of the users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Control of intermittent exotropia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first dose of fentanyl rescue analgesia intraoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total amount of additional intraoperative fentanyl rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time from recovery to first dose of pethidine rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total amount of pethidine postoperative rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in total scores on the Agitation-Aggression Psychiatric Inventory - Clinician Report (AAPI-CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total scores on the self-report Borderline Personality Disorder Checklist (BPDCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with clinically significant agitation and aggression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Puncture/drainage-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of immune-related adverse events (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: SF-36 Short Form 36 Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Eating Disorder Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Eating Disorder Symptoms using the EDE-Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-admission Percentage
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-efficacy of nurses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fear of COVID-19 for nurses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: psychological distress for nurses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: quality of life for nurses
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Concentration of CKD-846
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of D091
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum post-operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent restenosis rate (ISR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Barthel Index Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional autonomy measure (total score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Soft tissue modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fatty liver changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive range of motion of shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in foot function index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static standing balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of hepatic decompensation event
Endpoint domain: Adverse events/effects
Primary endpoint: Initiation of the HPV Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathologic Complete Response (pCR) Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Education and communication needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Specificity for MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Conversion from unresectable to resectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of related treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Developmental endothelial locus-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Soluble P-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harris Hip score evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adequate gastric decompression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric injury
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Minutes to Return of Baseline Muscle Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of care and treatments received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of complete aneurysm occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhagic, ischemic events, or neurological deficits
Endpoint domain: Adverse events/effects
Primary endpoint: The Short Physical Performance Battery (SPPB) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in WASO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Mean evolution time of tenosynovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Feeding Attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Re-hospitalizations and/or hospitalization extensions rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Absolute change in HVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Enrolled Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of comprehensive genomic analysis completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of successful return of clinical genetic/genomic results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in quality of life questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: blood loss during the perioperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ostomy reversal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EEG relative power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment success as described by the composite outcome of probing pocket depth (PPD) ≤5 mm, absence of bleeding on probing (BoP) and/or suppuration and bone loss ≤0.5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total colony forming units (CFU) counts of the bacterial species under study in targeted implants with peri-implantitis from Baseline to Week 6 after non-surgical therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean total colony forming units (CFU) counts of the bacterial species under study in targeted implants with peri-implantitis from Baseline to 12 months after surgical therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glycemic Index (GI) of the white bread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of identical medication anamneses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of Life for Constipation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Curve From Dosing to Infinity (AUC0-inf) of MK-3402
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration at the End of Infusion (Ceoi) of MK-3402
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of MK-3402
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of avidin-biotin-Dota-90Y
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor activity of avidin-biotin-Dota-90Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bio-impedance analysis muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bio-impedance analysis trunk fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of early infection after bipolar hemiarthroplasty
Endpoint domain: Adverse events/effects
Primary endpoint: Survival of the intravenous catheter
Endpoint domain: Mortality/survival
Primary endpoint: First-stick success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gamma oscillations assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Induction of 40 Hz Gamma oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of hyperglycemia events (blood glucose >150mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of high systolic blood pressure events (>95% centile for gestational age)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of infants who do not pass the ACTH stimulation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants experiencing adverse events (AEs)/serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Model Sensitivity (Recall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model Positive Predictive Value (Precision)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model Negative Predictive Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Sacral Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testis-to-ring distance in mm at the second stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testicular volume in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of serious bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: New ischemic lesion on postoperative MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intestinal side effects of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Homeostatic model assessment of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Harmless acute pancreatitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity to genotype-guided pharmacotherapy recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of hospitalizations attributable to FMT
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of abnormal ASQ-3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Opioid Overdose Risk Behaviors Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HIV/HCV Risk Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of GCV-R CMV-infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: impact of telehealth on clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, duration and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency, duration and severity of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sealant Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical status of subjects with different phenotypes and stages of CHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of employable and working subjects with different phenotypes and stages of CHF
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of subjects with a verified diagnosis of CHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients positive for BE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of ventilations with VTe between 4-8ml/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Femoral Neck Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Society Short Form (KSSF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ-5D-3L Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with MAPS Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to next treatment (TTNT)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functional Movement Screening Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from baseline in serotonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hair counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Response to induction therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Rating Scale for Depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of intrusive memories of traumatic event(s)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of major adverse cardiovascular events (MACEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thoracic fluid content measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RMS value of the EMG signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder-intact event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Bisphenol A Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer of antigen-specific IgGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-gamma secretion by T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of volatile sulphur compounds (VSC) in ppb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Continued Abstinence Rate (2 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Continued Abstinence Rate (1 month)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Continued Abstinence Rate (3 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skindex-29 domain scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burden of pruritus
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abdominal trunk function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants screened for substance use disorder
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of patients with hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient wound odour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dermatologic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum level of PFAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steroid free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of urinary extracellular vesicle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biliary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in anxiety severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Inventory Recovery Outcome Counter (I.ROC) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life